Clinical Practice Session
Clinical Updates in Onconephrology: Cardiovascular-Kidney-Metabolic Complications and Therapeutic Strategies
October 24, 2026 | 04:30 PM - 06:00 PM
Location: Four Seasons Ballroom 4, Convention Center
Session Description
This session provides a clinically focused update on cardiovascular-kidney-metabolic (CKM) complications in patients with cancer, highlighting mechanisms, risk stratification, and practical management strategies. Nephrology professionals are equipped with evidence-based approaches to manage hypertension and mitigate kidney and cardiovascular risk, including the emerging use of SGLT2 inhibitors and GLP-1 receptor agonists in oncology populations.
Learning Objective(s)
- Identify the key CKM complications associated with contemporary cancer therapies and their underlying pathophysiology
- Develop practical strategies to assess and mitigate kidney and cardiovascular risk in patients receiving anticancer treatments
- Summarize evidence-based approaches to diagnose and manage hypertension in oncology patients, including therapy-specific considerations
- Evaluate the emerging role of SGLT2 inhibitors and GLP-1 receptor agonists in improving CKM outcomes in patients with cancer
Learning Pathway(s)
- Onconephrology
- Cardiovascular-Kidney-Metabolic (CKM) Health
Moderators
Presentations
-
Managing Hypertension in Patients with Cancer: Practical Approaches to Vascular Endothelial Growth Factor Inhibitors, Tyrosine Kinase Inhibitors, and Metabolic Risk
-
Preventing Kidney and Cardiovascular Injury in Patients with Cancer: Risk Stratification and Mitigation
-
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients with Cancer
-
Sarcopenia, Weight Composition, and GFR Discordance in Cancer
-
Q&A